In addition, the SERPINC1 gene encodes the antithrombin III protein, which was identified in our cohort to be correlated with tumor size and can serve as a monitoring biomarker; medicines targeting SERPINC1 have been approved for venous thrombosis and coagulation defect treatment, although the combinatorial effect of SERPINC1-targeted therapy with anti-PD1 antibodies has yet to be explored. The gene discussed is SERPINC1; the disease is Venous thrombosis.